Dyadic Logo Current.jpg
Dyadic Announces Initiation of Dosing of First-In-Human Phase 1 Trial to Demonstrate Clinical Safety and Antibody Response in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate
24 janv. 2023 08h30 HE | Dyadic International, Inc.
JUPITER, Fla., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building...
New Logo.png
Provectus Biopharmaceuticals Receives Notice of Allowance for Refractory Pediatric Solid Tumor Cancer Monotherapy and Combination Therapy Patent for PV-10® Immunotherapy from United States Patent and Trademark Office
23 mars 2021 07h00 HE | Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, March 23, 2021 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the United States Patent and Trademark Office (USPTO) has allowed US patent application 16/412,872,...
Dyadic Logo Current.jpg
Dyadic Advancing Towards Human Clinical Trial of its SARS-CoV-2-S-RBD vaccine candidate, DYAI-100
18 mars 2021 08h30 HE | Dyadic International, Inc.
Israel Institute for Biological Research (IIBR) reports successful challenge studies using human ACE2 transgenic mice vaccinated with SARS-CoV-2-S-RBD vaccine candidate manufactured from...
provectus_logo.jpg
Provectus Biopharmaceuticals Announces Acceptance of PV-10® Melanoma Abstract for Oral Presentation at Melanoma Bridge 2020
12 nov. 2020 08h00 HE | Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from the Company's ongoing Phase 1b/2 study of autolytic cancer immunotherapy PV-10, an injectable...